We are currently investigating intermittent issues affecting access to some articles and pages on our site. We apologize for any inconvenience and are working to resolve this as quickly as possible.

IN BRIEF: Arecor Therapeutics shares tumble as plans Tetris wind-down

Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Announces the ...

Alliance News 10 January, 2025 | 9:21PM
Email Form Facebook Twitter LinkedIn RSS

Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Announces the orderly cessation of operations within the Tetris Pharma subsidiary, and a mutual agreement with Xeris BioPharma Holdings Inc to return the group's rights to medication Ogluo. Forms part of the group's strategic review. This concludes that rising supply chain costs and fixed selling prices have significantly reduced margins for Ogluo. In addition, the 2025 revenue outlook for non-Ogluo sales has been materially reduced in light of a partner losing a key NHS tender, materially reducing 2025 revenues for non-Ogluo products. The strategic decision to cease Tetris Pharma operations will enable the group to focus its efforts and resources on opportunities that offer "higher potential for value creation."

Current stock price: 60.00 pence, down 19% in London on Friday

12-month change: down 64%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Arecor Therapeutics PLC Ordinary Shares 58.50 GBX -20.95 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures